Shareholders of Teva Pharmaceutical Industries ( TEVA) and Ivax ( IVX) voted Thursday to support the companies' planned $7.4 billion combination. If the deal is approved by regulators, Israel-based Teva's acquisition of Miami-based Ivax will create the largest generic drugmaker in the world, supplanting the Sandoz unit of Novartis ( NVS ADR). More than 98% of the Teva and Ivax shares that were voted were cast in favor of the deal, the companies said. The Federal Trade Commission has asked the companies for additional information about the pact that was announced in late July. Teva and Ivax expect to close the transaction later this year or early next year.